New cobalt-mediated methods for the synthesis of bioactive triterpenoid natural products
Active Project Grant Awarded
- Award ID
- R15GM163256
- Recipient
-
Old Dominion University UEI ELA9KB9GJCN8 Part of Old Dominion University Research Foundation
- Awarding agency
-
National Institute of General Medical Sciences
National Institutes of Health, Department of Health and Human Services
- Obligated
- $580,064
Award facts
- Assistance listing
- 93.859 Biomedical Research and Research Training
- Completion date 13% complete
- Place of performance
- Norfolk, VA 23529, USA
Award details come from USAspending.gov.
About this award
The National Institute of General Medical Sciences awarded Old Dominion University $580,064 on June 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop cobalt-mediated catalytic methods for synthesizing bioactive triterpenoid natural products.
The work advances operationally-simple catalytic protocols employing bench-stable cobalt(III) complexes to enable carbon-carbon bond formation reactions—including carbonyl additions and allylboration reactions—for the synthesis of biologically relevant natural products, agrochemicals, and pharmaceuticals. The methods will contribute fundamental knowledge on first-row transition metal catalyst reactivity to support cost-effective and safer chemical processes. The research will demonstrate utility through total synthesis of sodwanones A-C and sodwanone H, compounds exhibiting nanomolar activity against A549 lung cancer cell lines with potential to serve as lead compounds for biochemical investigation and as a new class of antibiotics and sporicidal agents.
The performance period runs through May 31, 2029, with work performed in Norfolk, Virginia. Old Dominion University Research Foundation serves as the fiscal and administrative agent for the award.
Description
- Abstract
- The development of new, concise, and modular approaches toward physiologically important natural products that are synthetically flexible and amenable to late-stage modification is important for accessing new lead compounds and novel structural motifs for investigation as therapeutics to treat human disease. Provided that from 1981-2020 roughly 65% of all FDA approved drugs were influenced by natural products research, the unique molecular scaffolds found in nature are excellent starting points for the discovery of new lead therapeutics. While there are many factors to consider when developing a lead compound, structural complexity has become an increasingly important factor for clinical success in recent years. This work will advance new operationally-simple catalytic protocols employing bench-stable cobalt(III) complexes to build synthetically useful motifs through carbon-carbon bond formation reactions including carbonyl additions and allylboration reactions that are high utility for the synthesis of biologically relevant natural products, agrochemicals, and pharmaceuticals. The methods advanced in this work will contribute fundamental knowledge on the reactivity of first-row transition metal catalysts to help facilitate their use in new, cost-effective, and safer chemical processes. The utility and enabling power of the protocols developed with cobalt(III)-based catalysts in this work will be demonstrated through applications in the total synthesis biologically relevant triterpenoid natural products. This will lead to the first total synthesis of the sodwanones a-c and sodwanone h, which exhibits 2 NM nanomolar activity against A549 lung cancer cell lines and has the potential to serve as a lead compound for further biochemical investigations. The newly prepared compounds have a high potential to serve as a new class of antibiotics and sporicidal agents against c. Difficile providing a new treatment for this common hospital acquired infection, thereby having a direct impact in solving an unmet challenge in healthcare. The pursuit of these aims will provide and expand research and training opportunities for 8 undergraduate students and one graduate student at old dominion university. Student trainees will develop important skillsets through cross-training in synthetic method development, total synthesis, organometallic chemistry, computational chemistry, medicinal chemistry, and biochemistry.
Quick answers
Who received award R15GM163256?
R15GM163256 was awarded to Old Dominion University by National Institute of General Medical Sciences (National Institutes of Health) on June 1, 2026.
How much is award R15GM163256 worth?
$580,064 has been obligated on R15GM163256.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award